Artivion (NYSE:AORT) Given New $32.00 Price Target at Oppenheimer

Artivion (NYSE:AORT - Free Report) had its price target boosted by Oppenheimer from $30.00 to $32.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other brokerages also recently weighed in on AORT. Needham & Company LLC reiterated a "buy" rating and issued a $30.00 price target on shares of Artivion in a research report on Friday, September 27th. Stifel Nicolaus increased their target price on Artivion from $28.00 to $30.00 and gave the stock a "buy" rating in a research note on Friday, September 13th. Finally, JMP Securities initiated coverage on Artivion in a research note on Wednesday, October 23rd. They set an "outperform" rating and a $33.00 target price for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $31.00.

Artivion Trading Down 0.9 %

Artivion stock traded down $0.27 during trading hours on Friday, reaching $28.71. 370,071 shares of the company's stock traded hands, compared to its average volume of 224,325. The company has a debt-to-equity ratio of 1.07, a quick ratio of 4.04 and a current ratio of 5.63. Artivion has a fifty-two week low of $13.18 and a fifty-two week high of $30.00. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -133.33 and a beta of 1.75. The firm's 50 day moving average is $26.16 and its 200-day moving average is $25.06.

Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.07 earnings per share for the quarter, beating analysts' consensus estimates of $0.03 by $0.04. The business had revenue of $98.02 million for the quarter, compared to the consensus estimate of $97.70 million. Artivion had a negative net margin of 2.22% and a positive return on equity of 3.81%. On average, analysts predict that Artivion will post 0.2 earnings per share for the current year.

Insider Transactions at Artivion

In other news, Director Anthony B. Semedo sold 9,709 shares of the firm's stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total transaction of $242,627.91. Following the completion of the transaction, the director now directly owns 34,159 shares of the company's stock, valued at $853,633.41. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Anthony B. Semedo sold 9,709 shares of the firm's stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total value of $242,627.91. Following the completion of the transaction, the director now directly owns 34,159 shares of the company's stock, valued at approximately $853,633.41. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jean F. Holloway sold 2,383 shares of the firm's stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $25.76, for a total transaction of $61,386.08. Following the completion of the transaction, the senior vice president now directly owns 165,099 shares of the company's stock, valued at $4,252,950.24. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 37,109 shares of company stock valued at $951,935 in the last ninety days. 8.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Artivion

A number of hedge funds and other institutional investors have recently modified their holdings of AORT. The Manufacturers Life Insurance Company increased its position in shares of Artivion by 3.2% in the second quarter. The Manufacturers Life Insurance Company now owns 15,301 shares of the company's stock worth $392,000 after purchasing an additional 481 shares during the period. Louisiana State Employees Retirement System grew its position in Artivion by 3.1% in the second quarter. Louisiana State Employees Retirement System now owns 19,900 shares of the company's stock valued at $510,000 after acquiring an additional 600 shares during the last quarter. Texas Permanent School Fund Corp grew its position in Artivion by 2.0% in the first quarter. Texas Permanent School Fund Corp now owns 34,129 shares of the company's stock valued at $722,000 after acquiring an additional 677 shares during the last quarter. nVerses Capital LLC bought a new position in Artivion in the second quarter valued at about $28,000. Finally, Price T Rowe Associates Inc. MD grew its position in Artivion by 5.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 33,690 shares of the company's stock valued at $713,000 after acquiring an additional 1,634 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company's stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.